AOD9604: A Research Overview

Introduction

AOD9604 is a synthetic hexadecapeptide derived from the C-terminal region of human growth hormone (hGH). The compound was developed as an investigational research tool to isolate the lipid-regulatory pharmacological properties of hGH from its growth-promoting and insulin-antagonizing characteristics. Research interest in AOD9604 has spanned preclinical animal models, in vitro adipose tissue studies, and multiple human clinical trials, generating a body of peer-reviewed literature in endocrinology and metabolic pharmacology. A substantial safety and tolerability dataset from six randomized, controlled human studies positions AOD9604 among the more thoroughly characterized synthetic hGH fragments in the published literature.

Background

Growth hormone exerts diverse physiological effects, including modulation of lipid metabolism in adipose tissue. Early pharmacological research sought to determine whether these lipolytic properties could be attributed to a specific structural domain of the hGH molecule, and whether a smaller synthetic peptide encoding that domain might replicate the metabolic activity while avoiding the systemic effects associated with full-length hGH, such as insulin resistance and elevated IGF-1.

This line of inquiry, pursued at Monash University in Australia during the early 1990s, identified the carboxyl-terminal region of hGH — specifically the sequence spanning residues 177 to 191 — as the domain associated with antilipogenic activity [1]. Subsequent work led to the development of a stabilized analogue designated AOD9604, in which a tyrosine residue is added at the N-terminus of the native 177–191 fragment, yielding a 16-amino acid sequence designated Tyr-hGH177–191 [2]. The N-terminal tyrosine modification was introduced specifically to confer greater in vivo stability relative to the unmodified fragment.

Chemistry and Structure

AOD9604 is a hexadecapeptide with the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, encompassing residues 177 through 191 of the mature hGH sequence and the added N-terminal tyrosine. The molecule contains a disulfide bridge between the two cysteine residues at positions 182 and 189 (in full-length hGH numbering), which contributes to conformational stability.

The molecular formula is C78H123N23O23S2 and the approximate molecular weight is approximately 1817 Da. The compound is synthesized via solid-phase peptide synthesis techniques and is structurally distinct from the GH receptor-binding domain of the intact hormone; accordingly, it does not competitively inhibit full-length hGH at the GH receptor [3]. The compound's chemical independence from the receptor-binding domain is a key property separating its pharmacological profile from that of full-length hGH.

Pharmacological Classification

AOD9604 is classified as a synthetic growth hormone C-terminal fragment with reported lipolytic and antilipogenic activity. It is not a GH receptor agonist. Research indicates that its mechanism of action operates through a pathway independent of the canonical GH receptor signaling axis and independent of IGF-1 secretion [2,3]. Detailed discussion of the proposed molecular mechanisms is covered in the AOD9604 mechanism of action article.

The compound does not belong to the glucocorticoid, androgen, insulin, or catecholamine pharmacological classes. It has been characterized in the literature as a lipid-metabolism-modulating peptide. The precise receptor target is an area of ongoing scientific investigation. Importantly, preclinical research consistently noted that AOD9604 — unlike full-length hGH — was not associated with hyperglycemia or changes in insulin secretion in the animal models studied [7].

Safety Profile

One of the most substantive contributions of the AOD9604 clinical program to the peer-reviewed literature is a well-characterized human safety dataset. A consolidated analysis by Stier, Vos, and Kenley (2013), encompassing six randomized, double-blind, placebo-controlled trials, reported that AOD9604 displayed a safety and tolerability profile indistinguishable from placebo across all study arms [4]. No statistically significant effects on serum IGF-1, fasting glucose, insulin, HbA1c, cortisol, or thyroid hormones were observed at any dose tested, and no serious adverse events attributable to AOD9604 were reported across the clinical program [4].

This safety characterization extends across multiple routes of administration and dose levels, and was supplemented by chronic animal toxicology studies spanning six months in rats and nine months in cynomolgus monkeys, as well as genotoxicity assessments including Ames testing, chromosomal aberration assay, and bone marrow micronucleus assay — all of which were reported as negative [5].

Regulatory Status

AOD9604 underwent a formal pharmaceutical development program under the sponsorship of Metabolic Pharmaceuticals Pty Ltd, an Australian biotechnology company. Six randomized, controlled trials were conducted, including a pivotal 536-subject, 24-week multicenter study known as the OPTIONS trial. While the OPTIONS study did not meet its pre-specified primary endpoint for body weight reduction across the full dose range and trial duration, the extensive safety and tolerability dataset generated across the development program laid the groundwork for a subsequent regulatory pathway [4].

Following the conclusion of the pharmaceutical development program, the accumulated safety dataset was submitted in support of a Generally Recognized as Safe (GRAS) determination from the United States Food and Drug Administration, for AOD9604's intended use as an ingredient in foods, beverages, and dietary supplements [5]. This GRAS determination reflects the compound's safety profile as established across its clinical and nonclinical development program. The GRAS designation is not an endorsement of therapeutic efficacy and does not constitute drug approval.

AOD9604 is not approved by the FDA as a drug for any therapeutic indication and is not listed on the FDA's approved drug products database (the Orange Book). Regulatory status in other jurisdictions varies; researchers working with this compound are responsible for confirming applicable local regulations.

Discovery History

The discovery lineage of AOD9604 traces to work by F.M. Ng and colleagues at Monash University beginning in the early 1990s. A 1993 study reported that a synthetic peptide corresponding to residues 177–191 of hGH demonstrated antilipogenic activity in isolated rat adipose tissue preparations, with activity comparable in magnitude to that of the intact hGH molecule [1]. A 1994 study reported reductions in cumulative body weight gain and adipose tissue mass in obese C57BL/6J (ob/ob) mice following chronic treatment with the synthetic hGH 177–191 peptide, providing initial in vivo evidence for metabolically relevant activity [6].

Metabolic Pharmaceuticals Pty Ltd licensed and further developed this research, introducing the N-terminal tyrosine modification to create the more stable AOD9604 analogue. The company conducted preclinical studies in rodent and primate models, followed by multiple human clinical trials across Phase I and Phase II development. A detailed chronological account of this program appears in the companion history article. Research-grade AOD9604 from SpartaLabs is verified by third-party HPLC purity testing and mass spectrometric identity confirmation for every batch. The pharmacological classification of AOD9604 as a GH fragment also distinguishes it from GH secretagogues such as tesamorelin, which acts upstream at the level of GHRH receptor stimulation rather than operating as a C-terminal hGH domain fragment.

References

1. Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochemistry and Molecular Biology International. 1993;30(1):187–196. PMID: 8358331.

2. Heffernan MA, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology. 2001;142(12):5182–5189. https://doi.org/10.1210/endo.142.12.8522

3. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. American Journal of Physiology – Endocrinology and Metabolism. 2000;279(3):E501–E507. https://doi.org/10.1152/ajpendo.2000.279.3.E501

4. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism. 2013;3(1–2):7–15. https://www.jofem.org/index.php/jofem/article/view/157

5. Moré MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. Journal of Endocrinology and Metabolism. 2014;4(3):116–126. https://jofem.org/index.php/jofem/article/view/213

6. Natera SH, Jiang WJ, Ng FM. Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide. Biochemistry and Molecular Biology International. 1994;33(5):1011–1021. PMID: 7987248.

7. Heffernan M, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity. 2001;25(10):1442–1449. PMID: 11673763.